Cidara Therapeutics Inc (CDTX)
19.00
+1.55
(+8.88%)
USD |
NASDAQ |
Nov 22, 15:47
Cidara Therapeutics Enterprise Value: -4.423M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -4.423M |
| November 20, 2024 | -20.84M |
| November 19, 2024 | -17.25M |
| November 18, 2024 | -21.97M |
| November 15, 2024 | -26.13M |
| November 14, 2024 | -25.35M |
| November 13, 2024 | -29.44M |
| November 12, 2024 | -32.61M |
| November 11, 2024 | -33.31M |
| November 08, 2024 | -32.26M |
| November 07, 2024 | -35.01M |
| November 06, 2024 | -33.95M |
| November 05, 2024 | -33.95M |
| November 04, 2024 | -35.57M |
| November 01, 2024 | -35.15M |
| October 31, 2024 | -35.78M |
| October 30, 2024 | -36.98M |
| October 29, 2024 | -33.03M |
| October 28, 2024 | -39.51M |
| October 25, 2024 | -38.60M |
| October 24, 2024 | -48.75M |
| October 23, 2024 | -47.76M |
| October 22, 2024 | -47.20M |
| October 21, 2024 | -48.32M |
| October 18, 2024 | -48.04M |
| Date | Value |
|---|---|
| October 17, 2024 | -48.82M |
| October 16, 2024 | -51.71M |
| October 15, 2024 | -55.72M |
| October 14, 2024 | -54.81M |
| October 11, 2024 | -52.62M |
| October 10, 2024 | -53.26M |
| October 09, 2024 | -50.93M |
| October 08, 2024 | -51.92M |
| October 07, 2024 | -48.96M |
| October 04, 2024 | -50.58M |
| October 03, 2024 | -51.99M |
| October 02, 2024 | -53.04M |
| October 01, 2024 | -52.62M |
| September 30, 2024 | -51.64M |
| September 27, 2024 | -88.78M |
| September 26, 2024 | -88.43M |
| September 25, 2024 | -88.22M |
| September 24, 2024 | -88.57M |
| September 23, 2024 | -87.86M |
| September 20, 2024 | -85.05M |
| September 19, 2024 | -81.88M |
| September 18, 2024 | -82.59M |
| September 17, 2024 | -82.51M |
| September 16, 2024 | -81.32M |
| September 13, 2024 | -80.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-112.92M
Minimum
Jul 11 2024
143.50M
Maximum
Mar 21 2023
38.49M
Average
40.68M
Median
Jul 14 2021
Enterprise Value Benchmarks
| Biomarin Pharmaceutical Inc | 11.76B |
| Arbutus Biopharma Corp | 527.85M |
| GlycoMimetics Inc | 6.243M |
| FibroGen Inc | 22.76M |
| Cue Biopharma Inc | 38.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.98M |
| Total Expenses (Quarterly) | 17.39M |
| EPS Diluted (Quarterly) | -2.45 |
| Earnings Yield | -133.5% |
| Normalized Earnings Yield | -34.06 |